The pipeline of targeted therapies under clinical development for primary Sjögren's syndrome: A systematic review of trials

Shiboski, 2016, American college of rheumatology/European league against rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology involving three international patient cohorts, Ann Rheum Dis, 76

Qin, 2015, Epidemiology of primary Sjögren's syndrome: a systematic review and meta-analysis, Ann Rheum Dis, 74, 1983, 10.1136/annrheumdis-2014-205375

2018, NK cells in autoimmune diseases: linking innate and adaptive immune responses, Autoimmun Rev, 17

Brennan, 2003, Sex steroid hormones in primary Sjögren's syndrome, J Rheumatol, 30, 1267

Kivity, 2014, Infection and autoimmunity in Sjogren's syndrome: a clinical study and comprehensive review, J Autoimmun, 51, 17, 10.1016/j.jaut.2014.02.008

Lessard, 2013, Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome, Nat Genet, 45, 1284, 10.1038/ng.2792

Yao, 2013, Type I interferons in Sjögren's syndrome, Autoimmun Rev, 12, 558, 10.1016/j.autrev.2012.10.006

Navarro-Mendoza, 2018, Cytokine markers of B lymphocytes in minor salivary gland infiltrates in Sjögren's syndrome, Autoimmun Rev, 10.1016/j.autrev.2018.02.003

Chasset, 2018, Targeting interferons and their pathways in systemic lupus erythematosus, Autoimmun Rev, 17, 44, 10.1016/j.autrev.2017.11.009

Felten, 2018, The 2018 pipeline of targeted therapies under clinical development for systemic lupus Erythematosus: a systematic review of trials, Autoimmun Rev, 17, 781, 10.1016/j.autrev.2018.02.011

Dass, 2008, Reduction of fatigue in Sjögren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study, Ann Rheum Dis, 67, 1541, 10.1136/ard.2007.083865

Meijer, 2010, Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial, Arthritis Rheum, 62, 960, 10.1002/art.27314

Devauchelle-Pensec, 2014, Treatment of primary Sjögren syndrome with rituximab: a randomized trial, Ann Intern Med, 160

Bowman, 2017, Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and Oral dryness in primary Sjögren's syndrome, Arthritis Rheum Hoboken NJ, 69, 1440, 10.1002/art.40093

Gottenberg, 2013, Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and rituximab registry, Ann Rheum Dis, 72, 1026, 10.1136/annrheumdis-2012-202293

Giacomelli, 2017, Autoimmun Rev, 16, 911, 10.1016/j.autrev.2017.07.012

Mariette, 2013, Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study, Ann Rheum Dis

Pollard, 2013, Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial, Ann Rheum Dis, 72, 146, 10.1136/annrheumdis-2012-202071

De Vita, 2014, Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy, Clin Exp Rheumatol, 32, 490

St. Clair

Meiners, 2014, Abatacept treatment reduces disease activity in early primary Sjögren's syndrome (open-label proof of concept ASAP study), Ann Rheum Dis, 73, 1393, 10.1136/annrheumdis-2013-204653

Tsuboi, 2015, Mod Rheumatol, 25, 187, 10.3109/14397595.2014.951144

Fischer

Fox, 1994, Cytokine mRNA expression in salivary gland biopsies of Sjögren's syndrome, J Immunol Baltim Md, 152, 5532

Koski, 2001, Tumor necrosis factor-alpha and receptors for it in labial salivary glands in Sjögren's syndrome, Clin Exp Rheumatol, 19, 131

Mariette, 2004, Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled trial of Remicade in primary Sjögren's syndrome (TRIPSS), Arthritis Rheum, 50, 1270, 10.1002/art.20146

Sankar, 2004, Etanercept in Sjögren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial, Arthritis Rheum, 50, 2240, 10.1002/art.20299

Norheim, 2012, Interleukin-1 inhibition and fatigue in primary Sjögren's syndrome--a double blind, randomised clinical trial, PLoS One, 7, 10.1371/journal.pone.0030123

Grisius, 1997, Salivary and serum interleukin 6 in primary Sjögren's syndrome, J Rheumatol, 24, 1089

Tishler, 1998, Elevated tear interleukin-6 levels in patients with Sjögren syndrome, Ophthalmology, 105, 2327, 10.1016/S0161-6420(98)91236-2

Yu, 2009, A low interleukin-2 receptor signaling threshold supports the development and homeostasis of T regulatory cells, Immunity, 30, 204, 10.1016/j.immuni.2008.11.014

Nayar, 2019, Phosphatidylinositol-3-Kinase Delta pathway a novel therapeutic target for Sjogren's syndrome, ACR Meet Abstr

Helmer, 2017, First-in-human studies of seletalisib, an orally bioavailable small-molecule PI3Kδ inhibitor for the treatment of immune and inflammatory diseases, Eur J Clin Pharmacol, 73, 581, 10.1007/s00228-017-2205-7

Horvath, 2004, The Jak-STAT pathway stimulated by interferon alpha or interferon beta, Sci STKE Signal Transduct Knowl Environ, 2004

Namour, 2015, Pharmacokinetics and pharmacokinetic/pharmacodynamic modeling of filgotinib (GLPG0634), a selective JAK1 inhibitor, in support of phase IIB dose selection, Clin Pharmacokinet, 54, 859, 10.1007/s40262-015-0240-z

Aouar, 2016, Dual role of the tyrosine kinase syk in regulation of toll-like receptor signaling in Plasmacytoid dendritic cells, PLoS One, 11, 10.1371/journal.pone.0156063

Vargas, 2013, Inhibitors of BTK and ITK: state of the new drugs for Cancer, autoimmunity and inflammatory diseases, Scand J Immunol, 78, 130, 10.1111/sji.12069

Bloom, 2016, Identification of Iguratimod as an inhibitor of macrophage migration inhibitory factor (MIF) with steroid-sparing potential, J Biol Chem, 291, 26502, 10.1074/jbc.M116.743328

Li, 2018, Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway, Sci Rep, 8

Zhang, 2018, Expression of interleukin-17 in primary Sjögren's syndrome and the correlation with disease severity: a systematic review and meta-analysis, Scand J Immunol, 87, 10.1111/sji.12649

Cao, 2010, Signaling and ligand interaction of ILT7: receptor-mediated regulatory mechanisms for plasmacytoid dendritic cells, Immunol Rev, 234, 163, 10.1111/j.0105-2896.2009.00867.x

Burge, 2017, Safety, pharmacokinetics, and pharmacodynamics of RSLV-132, an RNase-fc fusion protein in systemic lupus erythematosus: a randomized, double-blind, placebo-controlled study, Lupus, 26, 825, 10.1177/0961203316678675

Saegusa, 2002, Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity, J Clin Invest, 110, 361, 10.1172/JCI0214682

Theron, 2017, Pharmacodynamic monitoring of RO5459072, a small molecule inhibitor of Cathepsin S, Front Immunol, 8, 10.3389/fimmu.2017.00806

Seror, 2010, EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome, Ann Rheum Dis, 69, 1103, 10.1136/ard.2009.110619